Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07760961
PHASE2

Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia

Sponsor: Vogenx, Inc.

View on ClinicalTrials.gov

Summary

VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.

Official title: Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants With Post-Bariatric Hypoglycemia to Determine the Effect of Mizagliflozin on Hypoglycemia

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2026-10

Completion Date

2028-01

Last Updated

2026-08-12

Healthy Volunteers

No

Interventions

DRUG

Mizagliflozin 5 mg

5mg mizagliflozin capsules orally administered TID for 28 days

DRUG

Mizagliflozin 10 mg

10mg mizagliflozin capsules orally administered TID for 28 days

DRUG

Placebo

Placebo capsules orally administered TID for 28 days